Cite
HARVARD Citation
Postel-Vinay, S. et al. (n.d.). First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies. European journal of cancer. pp. S7-S8. [Online].